We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




C-Reactive Protein Assessed for Albuminuria Severity

By LabMedica International staff writers
Posted on 21 Feb 2018
Diabetes is a major cause of early morbidity and mortality in the world and is the leading cause of renal failure, non-traumatic amputations and blindness in adults. More...
Chronic hyperglycemia causes irreversible structural and functional changes in cells leading to the development of microvascular and macrovascular complications.

C-reactive protein is one of the most sensitive markers of subclinical inflammation, and its serum concentration is an indicator of intensity of low-grade chronic inflammation of the arterial wall. Measurement of total albuminuria in 24-hour urine is the gold standard for early detection of nephropathy and its prevention and the most sensitive prognostic factor for assessing the risk of developing clinical nephropathy.

Scientists at Cantonal Hospital Zenica (Zenica, Bosnia and Herzegovina) and their colleagues carried out a prospective study included 69 patients with diabetes mellitus type 2 (T2DM), both sexes (24 males, 45 females), aged 30-82 years. They were divided into two groups: 40 patients with T2DM and normoalbuminuria (T2DM-NA); and 29 patients with T2DM and microalbuminuria (T2DM-MA). Patients were hospitalized at the Department of Internal Medicine, Cantonal Hospital Zenica, in the period January-April 2014.

Biochemical analyses were performed for serum creatinine, urea, high sensitive C-reactive protein (hsCRP), and albumin in 24-hour urine samples. Immunonephelometry measurement of hsCRP was performed on the Nephelometer Analyzer BN II. The 24 urinary albumin measurements were performed using immunoturbidimetric method (PETINIA), and the HbA1c was measured by turbidimetric inhibition immunoassay (TINIA) and an analysis was performed using the Siemens’ Dimension Clinical Chemistry System analyzer.

The team reported that the frequency of patients in T2DM-NA and T2DM-MA groups was not significantly different in relation to sex and age. There was significant difference in relation to duration of diabetes. The mean glucose and HbA1c levels were significantly higher in T2DM-NA group comparing to T2DM-MA group. Serum creatinine, urea and hsCRP were significantly higher in T2DM-MA group compared to T2DM-NA group. Urinary albumin showed significantly positive correlation with the hsCRP, urea and creatinine. A one unit (mg/L) increase in hsCRP concentration was associated with 11.5% increase of odds of microalbuminuria.

The authors concluded that significantly higher values of serum hsCRP in patients with type 2 diabetes mellitus and microalbuminuria in comparison to those with normoalbuminuria as well as the correlation of values of inflammatory marker with urinary albumin implicate a low-grade inflammation in the progression of diabetic nephropathy. The study was published on February 1, 2018, in the journal Medicinski Glasnik.

Related Links:
Cantonal Hospital Zenica


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.